|
UHRF2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.36440000408911E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.09869999995482E-06 |
| Normal-vs-Stage2 |
1.2973999985455E-08 |
| Normal-vs-Stage3 |
6.68340000009593E-08 |
| Normal-vs-Stage4 |
8.2550000002346E-07 |
| Stage1-vs-Stage2 |
4.577700E-03 |
| Stage1-vs-Stage3 |
2.417900E-02 |
| Stage1-vs-Stage4 |
6.754500E-02 |
| Stage2-vs-Stage3 |
3.082600E-01 |
| Stage2-vs-Stage4 |
3.720600E-01 |
| Stage3-vs-Stage4 |
9.385800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.4424999994489E-07 |
| Normal-vs-AfricanAmerican |
3.424700E-03 |
| Normal-vs-Asian |
4.037000E-04 |
| Caucasian-vs-AfricanAmerican |
7.353800E-01 |
| Caucasian-vs-Asian |
6.224400E-01 |
| AfricanAmerican-vs-Asian |
9.773400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.90080000004056E-06 |
| Normal-vs-Female |
9.65610003067496E-09 |
| Male-vs-Female |
5.035800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.200080E-04 |
| Normal-vs-Age(41-60Yrs) |
4.25709999474222E-08 |
| Normal-vs-Age(61-80Yrs) |
3.06559999607714E-09 |
| Normal-vs-Age(81-100Yrs) |
3.381200E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.272000E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.081380E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.692560E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.655050E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.244000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.031600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.208500E-02 |
| Classical-VS-Follicular |
4.44969999999767E-05 |
| Classical-VS-Other |
9.766600E-01 |
| Classical-VS-Normal |
1.59278999999346E-05 |
| Tall-VS-Follicular |
4.792800E-01 |
| Tall-VS-Other |
3.803800E-01 |
| Tall-VS-Normal |
2.44169999999988E-05 |
| Follicular-VS-Other |
2.091200E-01 |
| Follicular-VS-Normal |
9.4911001280451E-10 |
| Other-VS-Normal |
1.025990E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.88729961950685E-10 |
| Normal-vs-N1 |
2.187400E-04 |
| N0-vs-N1 |
3.340200E-01 |
|
|
